Kilimanjaro Altitude Sickness: The Science Behind the Climb

Every year, approximately 5–10% of Kilimanjaro climbers are evacuated off the mountain for altitude-related illness. Most are preventable. Most are not the oldest or the least fit. They are simply the ones who ascended too fast for their body's physiology — or were not monitored closely enough to catch the early signs.

Why Kilimanjaro Is Uniquely Aggressive

Altitude sickness is not a measure of how hard you trained. It is a measure of how fast you ascended relative to your body's ability to adapt. And Kilimanjaro is one of the most compressed altitude gains on Earth.

Climbers ascend from Moshi at 890m to Uhuru Peak at 5,895m in 5–9 days. Above 3,000m — where altitude sickness risk begins — the average ascent rate is 700–1,000m per day. The body's minimum requirement for meaningful acclimatisation at a given altitude is 2–3 days of exposure. Yet Kili's faster itineraries give it none.

Compare this to Mt. Kenya (5,199m): climbers typically spend 4–5 days reaching the point where altitude becomes physiologically demanding. The Inca Trail takes 4 days to reach 4,215m. Both have lower AMS rates despite comparable maximum altitudes, purely because of the ascent profile.

Kilimanjaro's low latitude (3° south of the equator) means there is less atmospheric shielding from solar radiation, slightly reducing barometric pressure relative to latitude alone. The result: at 5,895m, the partial pressure of oxygen is roughly 40% of what it is at sea level. You are effectively operating at 60% of the oxygen your body is calibrated for.

The Physiology: What Is Actually Happening Inside Your Body

At sea level, your body breathes approximately 25,000 times per day, moving 10,000 litres of air through your lungs. Each breath brings oxygen into the bloodstream via haemoglobin in red blood cells and delivers it to muscles and brain. At altitude, the same breath brings in fewer oxygen molecules — barometric pressure is lower, meaning lower oxygen partial pressure.

The body responds to hypoxia through a cascade of adaptations. Within hours of arriving at altitude, ventilation increases — you breathe faster and deeper. The kidneys release erythropoietin (EPO), stimulating the bone marrow to produce more red blood cells over 4–7 days. Plasma volume initially decreases, concentrating red blood cells. Heart rate rises to pump more blood per minute. These adaptations are the goal of acclimatisation.

The problem on Kilimanjaro is that the ascent timeline outruns these adaptations. When the body cannot keep pace, the result is a spectrum of altitude illness:

• AMSAcute Mountain Sickness — the mildest form. Headache is the primary symptom, accompanied by nausea, fatigue, loss of appetite, and dizziness. Affects 50–77% of Kili climbers. Treatable with rest, hydration, and slowing the ascent.
• HACEHigh Altitude Cerebral Oedema — a build-up of fluid in the brain caused by hypoxia-induced permeability of cerebral blood vessels. Symptoms include confusion, loss of coordination (ataxia), slurred speech, and altered mental state. Can progress rapidly over hours. Medical emergency. Immediate descent is required.
• HAPEHigh Altitude Pulmonary Oedema — a build-up of fluid in the lungs due to hypoxia-induced uneven pulmonary vasoconstriction. Symptoms include breathlessness even at rest, cough, chest tightness, and inability to recover from exertion. Can occur independently of or simultaneously with HACE. Medical emergency. Immediate descent is required.

Who Is Most Vulnerable

No single factor reliably predicts altitude sickness susceptibility on Kilimanjaro. This surprises climbers who assume fitness is protective — it is not. Elite marathon runners, professional mountaineers, and Ironman finishers all develop AMS on Kili. Age, gender, prior altitude experience, smoking status, and aerobic capacity have all been studied and none consistently predict who gets sick.

The only consistent predictor is the rate of ascent. Faster itineraries mean higher AMS rates. A climber who developed mild AMS on the Inca Trail is at somewhat higher risk on Kili — the prior episode suggests an individual tendency toward slower adaptation. But for most climbers, susceptibility is essentially unpredictable, which is why professional operators monitor every climber identically regardless of self-reported fitness or past altitude experience.

Evidence-Based Prevention: The Three Rules

Altitude sickness cannot be fully prevented — susceptibility is genetic and unpredictable. But three interventions are consistently shown by altitude medicine research to reduce both the likelihood and severity of symptoms:

The Diamox Question

Acetazolamide — marketed as Diamox — is a carbonic anhydrase inhibitor. By causing the kidneys to excrete bicarbonate, it lowers blood pH slightly, which stimulates faster ventilatory adaptation to altitude. Multiple double-blind studies confirm it reduces AMS incidence by 40–50% when taken prophylactically at 125mg twice daily, starting 24 hours before ascent above 3,000m and continuing until descent below that altitude.

Common side effects include tingling in the fingers and toes (paraesthesia), increased urination, and altered taste of carbonated drinks — notably flat Soda Stream-style sensation. These are not allergic reactions. They typically subside within 2–3 days of continued use.

Diamox is not a substitute for slow ascent. Climbers who take Diamox but continue on a fast itinerary still develop AMS at rates higher than climbers on a slow itinerary without Diamox. It is an adjunct to the three rules above, not a replacement for any of them. We advise climbers to discuss it with their personal physician before the climb — it is a prescription medication and not appropriate for everyone (contraindicated in sulfa allergies, certain kidney conditions, and pregnancy).

How Our Guides Monitor Altitude Risk

Every guide on every climb conducts the same monitoring protocol — regardless of the climber's fitness level, age, or self-reported how they feel. The reason is simple: subjective self-reporting is unreliable at altitude. Hypoxia impairs judgment. Climbers who are developing HACE often genuinely believe they are fine.

Frequently Asked Questions